Product Description
Overall, the global cerebrospinal fluid management market was valued at approximately $280 million in 2022. This is expected to increase over the forecast period at a CAGR of 2.1% to reach approximately $320 million.
The full report suite on the global market cerebrospinal fluid management market (CSF) includes the CSF shunt and CSF drainage shunt segments.
MARKET REPORT DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2029, and Historical Data to 2019
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
GLOBAL CEREBROSPINAL FLUID MANAGEMENT MARKET INSIGHTS
The number of unit sales is expected to increase as the population ages, but the number is not expected to change significantly in well-developed countries. The growth rates of BGS are expected to be higher in lower-income countries as healthcare becomes more accessible to people with time. As ASPs continue to decrease over time, this will limit the market growth.
GLOBAL CEREBROSPINAL FLUID MANAGEMENT MARKET SHARE INSIGHTS
Within the global market for cerebrospinal fluid management market is dominated by three key players – Medtronic, Integra Lifesciences, and Aesculap.
In 2022, Medtronic was the leader in the cerebrospinal fluid management market due to its strong position in the shunt segment and the drainage segment. The company offers the adjustable PS Medical® Strata® valves, which enables non-invasive adjustment by physicians with hand-held tools. These valves also have over-drainage protection and can be attached to a ventricular or distal catheter. These valves are MRI compatible.
MARKET SEGMENTATION SUMMARY
- Cerebrospinal Fluid Shunt Market
- Cerebrospinal Fluid Drainage Stunt Market
RESEARCH SCOPE SUMMARY
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam) Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2022 |
| Forecast | 2023-2029 |
| Historical Data | 2019-2022 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
WHY CHOOSE IDATA?
- Experts Only – iData has been around for over 17 years and is the trusted source of intelligence, and data-driven insights for key industry players. We are made up of specialists with a sole focus on medical devices, dental devices and pharmaceuticals. Our research and consulting field of endeavour never strays from the medical device industry and, because of this, we are the number one choice for leading companies in this field.
- Global Coverage – iData’s unique methodology, and its expansion to over 70 countries world-wide, has made it one of the most viable sources of intelligence for global companies along with those who plan to expand their portfolio beyond the confines of their own country. Providing procedural data at the country level is another testimony to the trusted global coverage we provide.
- Attention to Detail – It’s our attention to small details, scheduling of timelines, and keen project management that makes us stand out from the rest. We are creative, and our reports include metrics such as procedure numbers, ASPs, and SKU-level insights that are not found elsewhere.
- Pricing – When comparing like-with-like, iData’s prices are not only extremely competitive but also the most cost-effective. We strive for success and want the same for our clients. With the level of detail incorporated into each report alongside the extensive segmentation provided, no other report compares at our price point.
